文献速递鼻科

鼻内贝伐珠单抗注射改善遗传性出血性毛细血管扩张症患者的生活质量

Intranasal bevacizumab injections improve quality of life in HHT patients.
PubMed 文献 · Laryngoscope · 2019-07-09

这项前瞻性非对照研究纳入2011年6月至2013年8月接受重复鼻内黏膜下贝伐珠单抗注射(RISBI)治疗遗传性出血性毛细血管扩张症(HHT)相关鼻出血的患者,23例完成生活质量问卷。总体生活质量均值从6.47±1.9改善至7.26±1.6(P<.05),SF-36多个维度显著改善,HADS显示心理困扰显著下降。作者认为RISBI是中度至重度HHT相关鼻出血的有效治疗选择。

要点

  • 23例完成问卷,人均治疗2.15±1.3次(范围1-5次)。
  • 总体生活质量均值从6.47±1.9升至7.26±1.6(P<.05)。
  • SF-36多个维度显著改善,HADS心理困扰显著下降。

核心结论

  • 接受RISBI治疗的HHT患者在多个生活质量方面得到改善,心理困扰下降。
  • 作者认为RISBI是中度至重度HHT相关鼻出血的有效治疗选择。

研究设计与样本

  • 前瞻性非对照研究,2011年6月至2013年8月接受RISBI治疗HHT相关鼻出血的患者被前瞻性邀请入组,随访终点为2013年10月。
  • 33例患者接受RISBI治疗,其中23例完成生活质量问卷。

主要发现

  • 人均治疗次数为2.15±1.3次(范围1-5次)。
  • 总体生活质量均值从6.47±1.9改善至7.26±1.6(P<.05)。
  • SF-36测量的多个维度显著改善,效应量为中等至强。
  • HADS显示末次治疗后心理困扰显著下降。

局限性

  • 证据等级为4级(病例系列)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Epistaxis is the most common symptom in patients with hereditary hemorrhagic telangiectasia (HHT), with the greatest negative impact on quality of life (QoL). Repeated intranasal submucosal bevacizumab injections (RISBI) is a relatively new treatment option for moderate or severe grades of epistaxis in HHT. However, the effect of RISBI on QoL is not fully evaluated. STUDY DESIGN: Prospective, non-comparative study. MATERIALS AND METHODS: Patients treated by RISBI for HHT-associated epistaxis between June 2011 and August 2013 were prospectively invited to the present study. The end of follow-up was October 2013. The patients were requested to answer QoL questionnaires before the first treatment, and 6-8 weeks after the last treatment. Three levels of QoL were assessed: Overall QoL using Cantril's Self-Anchoring Ladder; Health-related QoL using Short Form 36 (SF-36), and Disease-specific QoL. Psychological distress was measured with the Hospital Anxiety and Depression scale (HADS). RESULTS: Thirty-three patients were treated with RISBI during the period referred to above. Twenty-three patients completed the QoL questionnaires. The average number of treatments per patient was 2.15 ± 1.3 (Range: 1-5). The mean overall QoL improved from 6.47 ± 1.9 to 7.26 ± 1.6 (P < .05). Several dimensions measured by SF-36 were significantly improved with a medium to strong effect size. HADS demonstrated a significant decrease in psychological distress after the last treatment. CONCLUSION: HHT patients treated by RISBI improved in several aspects of quality of life, and psychological distress decreased. RISBI was an effective treatment option for moderate and severe grades of HHT-associated epistaxis. LEVEL OF EVIDENCE: 4 (case series). Laryngoscope, 130:E284-E288, 2020.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Steineger J, Geirdal AØ, Osnes T, et al. Intranasal bevacizumab injections improve quality of life in HHT patients. Laryngoscope. 2019. PMID: 31287573. doi:10.1002/lary.28179

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。